CME in Minutes: Education in Primary Care

Please visit answersincme.com/CZS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Giuseppe Curigliano, MD, PhD. In this activity, an expert in oncology discusses the differentiation of patients with HER2-low/ultralow/negative advanced breast cancer and treatment with antibody-drug conjugates. Upon completion of this activity, participants should be better able to: Differentiate HER2-low, -ultralow, and -negative advanced breast cancer; Identify patients with HER2-low and -ultralow advanced breast cancer who would benefit from treatment with antibody-drug conjugates; and Apply evidence-based strategies to connect testing to treatment in patients with HER2-low or -ultralow advanced breast cancer.

Please visit answersincme.com/860/160204316-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tina Bhutani, MD, MAS, FAAD; and Robin K. Dore, MD. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.

Please visit answersincme.com/YMM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nitish Mehta, MD; and Sarwar Zahid, MD. In this activity, experts in diabetic retinopathy discuss long-acting anti-VEGF agents and strategies to improve outcomes for patients with diabetic macular edema (DME). Upon completion of this activity, participants should be better able to: Recognize factors that contribute to patients' treatment burden with intravitreal anti-VEGF therapies for diabetic macular edema (DME); Assess the clinical profiles of long-acting intravitreal anti-VEGF agents for DME; and Recommend individualized strategies to enhance long-term treatment outcomes for patients with DME.

Please visit answersincme.com/RCG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Raymond Osarogiagbon, MD, MBBS, FACP, FASCO; and Michael Gieske, MD. In this activity, experts in lung cancer discuss practical strategies for lung cancer screening. Upon completion of this activity, participants should be better able to: Recognize barriers to achieving lung cancer screening for eligible patients; Identify patients at high risk of lung cancer who are eligible for screening; and Outline practical, patient-centered strategies to appropriately integrate lung cancer screening into routine practice.

Please visit answersincme.com/860/29264-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aditya Bardia, MD and Tiffany A. Traina, MD, FASCO. In this activity, experts in breast cancer share evidence-based insights on integrating current and emerging TROP2-directed antibody-drug conjugates (ADCs) into real-world triple-negative breast cancer (TNBC) care. Upon completion of this activity, participants should be better able to: Identify the role of TROP2-directed antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer (TNBC) treatment; Compare the latest clinical data on available and emerging TROP2-targeting ADCs for the first-line treatment of patients with TNBC; and Discuss evidence-based strategies to optimize the selection of appropriate patients for first-line treatment with TROP2-targeting ADCs.